DK1358159T3 - 3,4-diaminopyridintartrat og phosphat, farmaceutiske præparater og anvendelser deraf - Google Patents

3,4-diaminopyridintartrat og phosphat, farmaceutiske præparater og anvendelser deraf

Info

Publication number
DK1358159T3
DK1358159T3 DK02701374T DK02701374T DK1358159T3 DK 1358159 T3 DK1358159 T3 DK 1358159T3 DK 02701374 T DK02701374 T DK 02701374T DK 02701374 T DK02701374 T DK 02701374T DK 1358159 T3 DK1358159 T3 DK 1358159T3
Authority
DK
Denmark
Prior art keywords
phosphate
pharmaceutical compositions
diaminopyridine
tartrate
diaminopyridine tartrate
Prior art date
Application number
DK02701374T
Other languages
English (en)
Inventor
Francois Guyon
Dominique Pradeau
Hoang My Dung Le
Jean-Jacques Houri
Original Assignee
Assist Publ Hopitaux De Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assist Publ Hopitaux De Paris filed Critical Assist Publ Hopitaux De Paris
Application granted granted Critical
Publication of DK1358159T3 publication Critical patent/DK1358159T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK02701374T 2001-02-05 2002-02-01 3,4-diaminopyridintartrat og phosphat, farmaceutiske præparater og anvendelser deraf DK1358159T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0101495A FR2820423B1 (fr) 2001-02-05 2001-02-05 Tartrate et phosphate de 3,4-diaminopyridine, compositions pharmaceutiques et utilisations
PCT/FR2002/000387 WO2002062760A1 (fr) 2001-02-05 2002-02-01 Tartrate et phosphate de 3,4-diaminopyridine, compositions pharmaceutiques et utilisations

Publications (1)

Publication Number Publication Date
DK1358159T3 true DK1358159T3 (da) 2009-11-23

Family

ID=8859598

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02701374T DK1358159T3 (da) 2001-02-05 2002-02-01 3,4-diaminopyridintartrat og phosphat, farmaceutiske præparater og anvendelser deraf

Country Status (9)

Country Link
US (3) US20040106651A1 (da)
EP (1) EP1358159B1 (da)
CY (1) CY1109496T1 (da)
DE (1) DE60233030D1 (da)
DK (1) DK1358159T3 (da)
ES (1) ES2330725T3 (da)
FR (1) FR2820423B1 (da)
PT (1) PT1358159E (da)
WO (1) WO2002062760A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2840591A1 (en) 2011-06-30 2013-01-03 Biomarin Pharmaceuticals, Inc. Methods of administering 3,4-diaminopyridine
EP3412656A1 (en) 2017-06-08 2018-12-12 Alfred E. Tiefenbacher (GmbH & Co. KG) Crystalline forms of amifampridine dihydrochloride
EP3696169B1 (en) 2019-04-18 2023-01-11 Alfred E. Tiefenbacher (GmbH & Co. KG) Manufacturing process for amifampridine phosphate
JP2022542659A (ja) * 2019-08-06 2022-10-06 カタリスト ファーマシューティカルズ， インコーポレイテッド 性機能不全を処置するための方法
WO2023023463A1 (en) * 2021-08-19 2023-02-23 Catalyst Pharmaceuticals, Inc. Method for treating botulinum toxin poisoning
CN114712321B (zh) * 2022-04-22 2024-05-24 河北一品生物医药有限公司 磷酸二氨基吡啶缓释片及其制备方法
DE102022126035A1 (de) 2022-10-07 2024-04-18 Thomas Böhmeke Verwendung von Aminopyridin bei der Behandlung einer Fatigue

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4386095A (en) * 1982-02-22 1983-05-31 Cornell Research Foundation, Inc. Diaminopyridines to improve cognition
IL74373A0 (en) * 1984-02-21 1985-05-31 Lilly Co Eli Process for the preparation of diaminopyridines
US4562196A (en) * 1984-04-06 1985-12-31 Nelson Research & Development 2,4-Diaminopyridine as a pharmacologic agent
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
US5952357A (en) * 1993-12-23 1999-09-14 Cornell Research Foundation, Inc. Treating diseases of the anterior horn cells
SE9504537D0 (sv) * 1995-12-19 1995-12-19 Jan Hedner Sätt att behandla och diagnosticera andningsstörningar under sömn och medel för utförande av sättet
US5721215A (en) * 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
AU3360000A (en) * 1999-02-09 2000-08-29 Uab Research Foundation Use of 4-amino pyridine for treatment of peripheral neuropathies

Also Published As

Publication number Publication date
DE60233030D1 (de) 2009-09-03
WO2002062760A1 (fr) 2002-08-15
PT1358159E (pt) 2009-10-27
US20040106651A1 (en) 2004-06-03
FR2820423B1 (fr) 2005-12-02
EP1358159B1 (fr) 2009-07-22
EP1358159A1 (fr) 2003-11-05
FR2820423A1 (fr) 2002-08-09
US20140080875A1 (en) 2014-03-20
ES2330725T3 (es) 2009-12-15
CY1109496T1 (el) 2014-08-13
US20150353467A1 (en) 2015-12-10

Similar Documents

Publication Publication Date Title
EE200300370A (et) Atsüülitud 6,7,8,9-tetrahüdro-5H-bensotsükloheptenüülamiinid, nende valmistamismeetod, kasutamine ja farmatseutiline preparaat
NO20033384D0 (no) Farmasöytisk formulering
EE200300369A (et) Atsüülitud indanüülamiinid, nende valmistamismeetod, kasutamine ja farmatseutiline preparaat
HUP0400467A3 (en) 2-iminopyrrolidine derivatives, pharmaceutical compositions containing them and their use
NO20033785D0 (no) Farmasöytisk formulering
GB0118689D0 (en) Pharmaceutical formulation
HUP0401638A3 (en) Thiopene-amides, thiazolesulfonamides as antineoplastic agents, and pharmaceutical composition containing the same
NO20035627D0 (no) Farmasöytisk formulering
HUP0401403A3 (en) 2,4-diaminothiazole derivatives, their use and pharmaceutical compositions containing them
HUP0500024A3 (en) 6-aminomorphinane derivatives, their use and pharmaceutical compositions containing them
HUP0400179A3 (en) 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines, their use and pharmaceutical compositions containing them
NO20041485L (no) Farmasoytisk formulering omfattende (R)-bicalutamid
DK1358159T3 (da) 3,4-diaminopyridintartrat og phosphat, farmaceutiske præparater og anvendelser deraf
DK1275647T3 (da) Octahydro-1H-pyrido[1,2-a]pyrazinderivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
IL160960A0 (en) Reduced toxicity cisplatin formulations and methods for using the same
MXPA03010259A (es) Nuevos derivados de 5-tio-ss-d-xilopiranosida, procedimiento de preparacion, composiciones farmaceuticas que los contienen y el uso terapeutico de los mismos.
GB0104749D0 (en) Pharmaceutical formulation
NO20041236L (no) Farmasoytisk formulering
NO20040408L (no) Fast frittflytende fosfatblanding og andvendelse derav.
SE0102957D0 (sv) Pharmaceutical formulation
SE0101171D0 (sv) Pharmaceutical formulation
SE0101325D0 (sv) Pharmaceutical formulation
SE0101326D0 (sv) Pharmaceutical formulation
SE0102572D0 (sv) Pharmaceutical formulation
SE0103565D0 (sv) Pharmaceutical formulation